SCHEMBL250282

SCHEMBL250282

CC(C(N)=O)c1ccccc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 1/20 0.49
EPHX1 P07099 2/20 0.43
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
PTGS2 P35354 1/20 0.38
CFTR P13569 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALOX5 P09917 1/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
ESRRA P11474 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9321170 0.87 CXCL8 (0.54) CXCL8EPHX1PTGS2HSD17B10ALOX5
SCHEMBL27304888 0.85 ALDH1A1 (0.40) CXCL8ALDH1A1KDM4EPTGS2CFTR
SCHEMBL30338418 0.83 PTGS2 (0.52) CXCL8ALDH1A1KDM4EPTGS2HSD17B10
SCHEMBL8203180 0.83 PTGS2 (0.42) CXCL8ALDH1A1KDM4EPTGS2CFTR
SCHEMBL5215577 0.83 PTGS2 (0.52) CXCL8ALDH1A1KDM4EPTGS2HSD17B10
SCHEMBL288752 0.83 PTGS2 (0.52) CXCL8ALDH1A1KDM4EPTGS2HSD17B10
SCHEMBL59839 0.83 PTGS2 (0.52) CXCL8ALDH1A1KDM4EPTGS2HSD17B10
SCHEMBL6405488 0.82 ALDH1A1 (0.38) CXCL8ALDH1A1KDM4EPTGS2CFTR
SCHEMBL14505423 0.82 ALDH1A1 (0.38) CXCL8ALDH1A1KDM4EPTGS2CFTR
SCHEMBL11514961 0.82 ALDH1A1 (0.38) CXCL8ALDH1A1KDM4EPTGS2CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1570 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11633494-B2 Compounds and compositions for immunotherapy BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2023-04-25 US claimed
US-11633495-B2 Compounds and compositions for immunotherapy BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2023-04-25 US claimed
CN-115181164-A Derivatives of amatoxins and their coupling to cell binding molecules 杭州多禧生物科技有限公司 2022-10-14 CN claimed
CN-115124573-A Novel cytotoxic molecules for use in cell binding molecule-drug conjugates 杭州多禧生物科技有限公司 2022-09-30 CN claimed
EP-4056594-A1 COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY Birdie Biopharmaceuticals Inc. (KY) 2022-09-14 EP claimed
CN-109689107-B Derivatives of amatoxins and their coupling to cell binding molecules 杭州多禧生物科技有限公司 2022-08-16 CN claimed
US-20220047711-A1 PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS GENENTECH, INC. (US) 2022-02-17 US claimed
EP-3894427-A1 PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS Genentech, Inc. (US) 2021-10-20 EP claimed
CN-113227119-A Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins 基因泰克公司 2021-08-06 CN claimed
US-10836796-B2 Derivatives of amanita toxins and their conjugation to a cell binding molecule HANGZHOU DAC BIOTECH CO., LTD. (CN) 2020-11-17 US claimed
US-20190269789-A1 COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY SHANGHAI BIRDIE BIOTECH, INC. (CN) 2019-09-05 US claimed
US-20190269790-A1 COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY SHANGHAI BIRDIE BIOTECH, INC. (CN) 2019-09-05 US claimed
US-10328158-B2 Compounds and compositions for immunotherapy BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2019-06-25 US claimed
EP-3041846-B1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO LTD (CN) 2018-11-07 EP claimed
US-9988408-B2 Cytotoxic agents for conjugation to a cell binding molecule HANGZHOU DAC BIOTECH CO., LTD. (CN) 2018-06-05 US claimed
WO-2017046658-A1 DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO, LTD (CN) 2017-03-23 WO claimed
US-20160207949-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO., LTD (CN) 2016-07-21 US claimed
EP-3041846-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE Hangzhou Dac Biotech Co., Ltd (CN) 2016-07-13 EP claimed
WO-2015028850-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO., LTD (CN) 2015-03-05 WO claimed
CN-86105641-A The method for preparing antianaphylaxis and antibronchospasm of N-dibenzyl-diazacyclo alkyl-alkyl-anilide 1987-04-01 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190269790-A1 COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY CD47, CD274, TP53 CXCL8 240/4885EPHX1 1941/4885ALDH1A1 1617/4885
US-11633494-B2 Compounds and compositions for immunotherapy CD47, CD274, TP53 CXCL8 240/4885EPHX1 1941/4885ALDH1A1 1617/4885
US-20160207949-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE PDCD5, CD4, PDCD6 CXCL8 2669/4885EPHX1 2956/4885ALDH1A1 1947/4885
US-10836796-B2 Derivatives of amanita toxins and their conjugation to a cell binding molecule ANTXR2, ANXA5, C3AR1 CXCL8 2893/4885EPHX1 4171/4885ALDH1A1 4490/4885
US-11633495-B2 Compounds and compositions for immunotherapy CD47, CD274, TP53 CXCL8 240/4885EPHX1 1941/4885ALDH1A1 1617/4885
US-20190269789-A1 COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY CD47, CD274, TP53 CXCL8 240/4885EPHX1 1941/4885ALDH1A1 1617/4885
US-10328158-B2 Compounds and compositions for immunotherapy CD47, CD274, TP53 CXCL8 240/4885EPHX1 1941/4885ALDH1A1 1617/4885
US-20220047711-A1 PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS FCGR2A, FCGR3B, DNPEP CXCL8 3749/4885EPHX1 1785/4885ALDH1A1 3261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.